A Study of Sovilnesib in Subjects With Ovarian Cancer

This is a phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of sovilnesib at different dose levels to establish the optimal dose of sovilnesib in subjects with selected advanced solid tumors.

Trial Details

NCT ID
NCT06084416
Phase
PHASE1
Sponsor
Volastra Therapeutics, Inc.
Status
RECRUITING
Cancer Type
High-Grade Serous Ovarian Cancer
Interventions
  • Sovilnesib
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Newport Beach, California, United States|33.61891,-117.92895
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • All Parts: Age ≥ 18 years, ECOG Performance Status ≤ 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to t…
  • Histologically confirmed locally advanced, inoperable, or metastatic tumor.
  • High Grade Serous Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer - histologically confirmed; locally advanced, inoperable or metastati…
  • Key Exclusion Criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →